The breast cancer continuum in hormone-receptor-positive breast cancer in postmenopausal women: Evolving management options focusing on aromatase inhibitors

Annals of Oncology

Volumn 19, Issue 1, 2008, Pages 16-27

  Rugo, H S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Anastrozole; Aromatase inhibitors; Breast cancer; Exemestane; Letrozole; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; ANTIESTROGEN; AROMATASE INHIBITOR; DOXORUBICIN; EXEMESTANE; FULVESTRANT; HORMONE RECEPTOR; LETROZOLE; MEGESTROL; MEGESTROL ACETATE; PACLITAXEL; PLACEBO; TAMOXIFEN; TAMOXIFEN CITRATE; TOREMIFENE; TRASTUZUMAB;

ADJUVANT THERAPY; ALOPECIA; ANOREXIA; ARTHRALGIA; BREAST CANCER; CANCER HORMONE THERAPY; CANCER SURVIVAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GYNECOLOGIC DISEASE; HEART INFARCTION; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; LOADING DRUG DOSE; METASTASIS; MONOTHERAPY; MUSCULOSKELETAL DISEASE; NEUTROPENIA; OSTEOPOROSIS; OVERALL SURVIVAL; PATHOLOGIC FRACTURE; POSTMENOPAUSE; PRIORITY JOURNAL; RECURRENCE RISK; REVIEW; RISK REDUCTION; THROMBOEMBOLISM; TREATMENT OUTCOME; VAGINA BLEEDING; VAGINA DISCHARGE; VASCULAR DISEASE;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; DISEASE MANAGEMENT; DOUBLE-BLIND METHOD; DRUG RESISTANCE, NEOPLASM; ESTROGEN RECEPTOR MODULATORS; ESTROGENS; FEMALE; HUMANS; MULTICENTER STUDIES AS TOPIC; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; SALVAGE THERAPY;

EID: 37849052460     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm282     Document Type: Review

References (77)

1. Geisler J. Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators. J Steroid Biochem Molec Biol 2003; 86: 245-253.
2. Miller WR, O'Neill J. The importance of local synthesis of estrogen within the breast. Steroids 1987; 50: 537-548.
3. Jensen EV, Jordan VC. The estrogen receptor: A model for molecular medicine. Clin Cancer Res 2003; 9: 1980-1989.
4. Allred DC, Bustamante MA, Daniel CO et al. Immunocytochemical analysis of estrogen receptors in human breast carcinomas. Arch Sung 1990; 125: 107-113.
5. Harvey JM, Clark GM, Osborne CK et al. Estrogen receptor status by immunohistochemistry is superior to the ligand-bincling assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999; 17: 1474-1481.
6. Allred DC, Harvery JM, Berardo M et al. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 1998; 11: 155-168.
7. Rhodes A, Jasani B, Barnes DM et al. Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems. J Clin Pathol 2000; 53: 125-130.
8. Layfield LJ, Goldstein N, Parkinson KR et al. Interlaboratory variation in results from immunohistochemical assessment of estrogen receptor status. Breast J 2003; 9: 257-259.
9. Nadji M, Gomez-Fernandez C, Ganjei-Azar P et al. Immunohistochemistry of estrogen and progesterone receptors reconsidered: Experience with 5,993 breast cancers. Am J Clin Pathol 2005; 123: 21-27.
10. Possinger K. Fulvestrant: A new treatment for postmenopausal women with hormone-sensitive advanced breast cancer. Expert Opin Pharmacother 2004; 5: 2549-2558.
11. Early Breast Cancer Trialists' Collaborative Group (EBCTGG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005; 365 (9472): 1687-1717.
12. Guarneri V, Conte PF. The curability of breast cancer and the treatment of advanced disease. Eur J Nucl Med Mol Imaging 2004; 31: S149-S161.
13. Fisher B, Costantino JP, Wickerham DL et al. Tamoxifen for prevention of breast cancer: Report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998; 90: 1371-1388.
14. Smith IE. Aromatase inhibitors: Extending the benefits of adjuvant therapy beyond tamoxifen. Breast 2004; 13: S3-S9.
15. Cuzick J, Powles T, Veronesi U et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet 2003; 361: 296-300.
16. Horwitz KB. Bringing estrogen receptors under control [commentary].Breast Cancer Res 1999: 1. http://breast-cancer-research.com/content/1/1/5 (20 May 2005, date last accessed).
17. DeFriend DJ, Howell A, Nicholson RI et al. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 1994; 54: 408-414.
18. Huober J, Krainick-Strobol U, Kurek R et al. Neoadjuvant endocrine therapy in primary breast cancer. Clin Breast Cancer 2004; 5: 341-347.
19. Seminiglazov VF, Seminigiazov V, Ivanov V et al. The relative efficacy of neoadjuvant endocrine therapy vs chemotherapy in postmenopausal women with ER-positive breast cancer. Proc Am Soc Clin Oncol 2004; 23: 7 (Abstr 519).
20. Kudachadkar R, O'Regan RM. Aromatase inhibitors as adjuvant therapy for postmenopausal patients with early stage breast cancer. CA Cancer J Clin 2005; 55: 145-163.
21. Buzdar A, Valero V, Theriault RL et al. Pathological complete response to chemotherapy is related to hormone receptor status. Breast Cancer Res Treat 2003: 82 (Abstr 302).
22. Eiermann W, Paepke S, Appfelstaedt J et al. Letrozole Neo-Adjuvant Breast Cancer Study Group. Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. Ann Oncol 2001; 12: 1527-1532.
23. Smith IE, Dowsett M, Ebbs SR et al. (IMPACT Trialists Group). Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: The Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol 2005; 23: 5108-5116.
24. Semiglazov V, Kletsel A, Semiglazov V et al. Exemestane (E) vs tamoxifen (T) as neoadjuvant endocrine therapy for postmenopausal women with ER+ breast cancer (T2N1-2, T3N0-1, T4N0M0). J Clin Oncol 2005; 23 (Suppl 16): 11S (Abstr 530).
25. Wolmark N, Wang J, Mamounas E et al. Preoperative chemotherapy in patients with operable breast cancer: Nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst 2001; 30: 96-102.
26. Cataliotti L, Buzdar AU, Noguchi S et al. Comparison of anastrozole versus tamoxifen as preoperative therapy in postmenopausal women with hormone receptor-positive breast cancer: Ahe Pre-Operative 'Animidex' Compared to Tamoxifen (PROACT) trial. Cancer 2006; 106: 2095-2103.
27. Ellis MJ, Coop A, Singh B et al. Letrozole is more effectve neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol 2001; 19: 3808-3816.
28. Ellis MJ, Rosen E, Dressman H et al. Neoadjuvant comparisons of aromatase inhibitors and tamoxifen: Pretreatment determinants of response and on-treatment effect. J Steroid Biochem Mol Biol 2003; 86: 301-307.
29. Ellis MJ et al. Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole. J Clin Oncol 2006; 24(19): 3019-3025.
30. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005; 23: 619-629.
31. Baum M, Budzar AU, Cuzick J et al. (ATAC Trialists' Group). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
32. Baum M, Buzdar A, Cuzick J et al. (ATAC Trialists' Group). Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: Results of the ATAC (Arimidex, Tamoxifen; Alone or in Combination) trial efficacy and safety update analyses. Cancer 2003; 98: 1802-1810.
33. Howell A, Cuzick J, Baum M et al. (ATAC Trialists' Group). Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005; 365: 60-62.
34. Buzdar AU, Guastalla JP, Nabholtz JM et al. (ATAC Trialists' Group). Impact of chemotherapy regimens prior to endocrine therapy: Results from the ATAC (Anastrozole and Tamoxifen, Alone or in Combination) trial. Cancer 2006; 107: 472-480, Erratum in: Cancer 2006; 107: 2314.
35. Buzdar A, Howell A, Cuzick J et al. (ATAC Trialists' Group). Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 2006; 7: 633-643.
36. Dowsett M, Cuzick J, Wale C et al. Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: An hypothesis-generating study. J Glin Oncol 2005; 23: 7512-7517.
37. Dowsett M, Allred DC, on behalf of the TransATAC investigators. Relationship between quantitative ER and PgR expression and HER2, status with recurrence in the ATAC trial. Breast Cancer Res Treat 2006; 100 (Suppl 1): S21 (Abstr 48).
38. Thürlimann B, Keshaviah A, Coates AS et al. (Breast International Group [BIG] 1-98 Collaborative Group). A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.
39. Viale G, Regan M, Dell'Orto P et al. (BIG 1-98 Collaborative International Breast Cancer Study Group). Central review of ER, PgR and HER-2 in BIG 1-98 evaluating letrozole vs.tamoxifen as adjuvant endocrine therapy for postmenopausal women with receptor-positive breast cancer. Breast Cancer Res Treat 2005; 94: 44.
40. Fisher B, Dignam J, Bryant J et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: Updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 2001; 93: 684-690.
41. Mouridsen HT, Robert NJ. The role of aromatase inhibitors as adjuvant therapy for early breast cancer in postmenopausal women. Eur J Cancer 2005; 41: 1678-1689.
42. Kaufmann M, Jonat W, Hilfrich J et al. on behalf of the German Adjuvant Breast Cancer Group. Survival benefit of switching to anastrozole after 2 years' treatment with tamoxifen versus continued tamoxifen therapy: the ARNO 95 study. J Clin Oncol 2006; 24(18S): 14S (Abstr 547).
43. Coombes RC, Hall E, Gibson LJ et al. (Intergroup Exemestane Study). A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
44. Coombes RC, Kilburn LS, Snowdon CF. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): A randomised controlled trial. Lancet 2007; 369: 559-570. Erratum in: Lancet 2007; 369: 906.
45. Jakesz R, Jonat W, Gnant M et al. on behalf of the ABCSG, the GABG. Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462.
46. Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol 2005; 23: 5148-5147.
47. Jones SE. Exemestane as adjuvant treatment of early breast cancer: intergroup exemestane study/tamoxifen exemestane adjuvant multicenter trials. Clin Breast Cancer 2006; 6 (Suppl 2): S41-S4.
48. Saphner T, Tormey DC, Gray R. Annual hazard rates of recurrence for breast cancer after primary therapy. J Clin Oncol 1996; 14: 2738-2746.
49. Hortobagyi GN, Kau S-W, Buzdar AU et al. What is the prognosis of patients with operable breast cancer (BC) five years after diagnosis? Proc Am Soc Clin Oncol 2004; 23: 23 (Abstr 585).
50. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
51. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005; 97: 1262-1271.
52. Goss PE, Ingle JN, Palmer MJ et al. Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs placebo) post unblinding. Breast Cancer Res Treat 2005; 94: 16.
53. Goss P. Update on the MA. 17 extended adjuvant trial. Best Pract Res Clin Endocrinol Metab 2005; 20 (Suppl 1): S5-S13.
54. Jakesz R, Samonigg H, Greil R et al. on behalf of the ABCSG. Extended adjuvant treatment with anastrozole: Results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). Proc Am Soc Clin Oncol 2005; 23 (Suppl 16): 10S (Abstr 526).
55. Mamounas E, Jeong J-H, Wickerham L et al. Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat 2006; 100 (Suppl 1): S22 (Abstr 49).
56. Carlson RW, Hudis CA, Pritchard KI et al. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: Evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw 2006; 4 (10): 971-979.
57. Hillner BE, Ingle JN, Chlebowski RT et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol 2003; 21: 4042-4057.
58. Bonneterre J, Buzdar A, Nabholtz JM et al. (Arimidex Writing Committee; Investigators Committee Members). Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma. Cancer 2001; 92: 2247-2258.
59. Nabholtz JIM, Budzar A, Pollak M et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: Results of a North American multicenter trial. J Clin Oncol 2000; 18: 3758-3767.
60. Paridaens R, Therasse P, Dirix L et al. First line hormonal treatment (HT) for metastatic breast cancer (MBC) with exemestane (E) or tamoxifen (I) in postmenopausal patients (pts): A randomized phase III trial of the EORTC Breast Group. Proc Am Soc Clin Onool 2004; 22 (S1): 515.
61. Mouridsen H, Gershanovich M, Sun Y et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol 2001; 19: 2596-2606.
62. Mouridsen H, Gershanovich M, Sun Y et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 2003; 21: 2101-2109.
63. Howell A, Roberston JFR, Abram P et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: A multinational, double-blind, randomized trial. J Clin Oncol 2004; 22: 1605-1613.
64. Robertson JFR, Come SE, Jones SE et al. Endocrine treatment options for advanced breast cancer: The role of fulvestrant. Eur J Cancer 2005; 41: 346-356.
65. Robertson JF, Harrison M. Fulvestrant: Pharmacokinetics and pharmacology. Br J Cancer 2004; 90 (Suppl 1): S7-S10.
66. Gradishar W, Chia SK, Piccart M. Fulvestrant versus exemestane following prior non-steroidal aromatase inhibitor therapy: First results from EFECT, a randomized, phase III trial in postmenopausal women with advanced breast cancer. Breast Cancer Res Treat 2006; 100 (S1): 12.
67. Buzdar AU. Advances in endocrine treatments for postmenopausal women with metastatic and early breast cancer. Oncologist 2003; 8: 335-341.
68. Bertelli G, Garrone O, Medano M et al. Sequential treatment withr exemestane and non-steroidal aromatase inhibitors in advanced breast cancer. Oncology 2005; 69: 471-477.
69. Thürlimann B, Robertson JF, Nabholtz JM et al. Efficacy of tamoxifen following anastrozole ('Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003; 39: 2310-2317.
70. Lonning PE, Bajetta E, Murray R et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: A phase II trial. J Clin Oncol 2000; 18: 2234-2244.
71. Gee JMW, Harper ME, Hutcheson IR et al. The antiepidermal growth factor receptor agent gefitinib (ZD1839/Iressa) improves antihormone response and prevents development of resistance in breast cancer in vitro. Endocrinology 2003; 144: 5105-5117.
72. Ellis M. Overcoming endocrine therapy resistance by signal transduction inhibition. Oncologist 2004; 9 (Suppl 3): 20-26.
73. Gradishar WJ. Tamoxifen: What next? Oncologist 2004; 9: 378-384.
74. Carlini P, Ferretti G, Di Cosimo S et al. Is there a benefit by the sequence anastrozole-formestane for postmenopausal metastatic breast cancer women? J Steroid Biochem Mol Biol 2003; 86: 107-109.
75. Robertson JF, Howell A, Gorbunova VA et al. Sensitivity to further endocrine therapy is retained following progression on first-line fulvestrant. Breast Cancer Res Treat 2005; 92: 169-174.
76. Johnston S. Fulvestrant and the sequential endocrine cascade for advanced breast cancer. Br J Cancer 2004; 90: S15-S18.
77. Mackay JR, Kaufman B, Clemens M et al. Trastuzumab prolongs progression-free survival in hormone-dependent and HER2-positive metastatic breast cancer. Breast Cancer Res Treat 2006; 100 (Suppl 1): S5-S6 (Abstr 3).